Background: Coronavirus induced disease-19 (COVID-19), is a serious disease induced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Liver cirrhosis and its complications are currently the ninth most common cause of death worldwide. This work aims to evaluate the impact of COVID-19 on mortality rate in patients with CLD.
Patients and methods: The current study included 120 patients with COVID-19 who were distributed according to the state of the liver affection into two groups; group 1 included 60 patients with combined COVID-19 and CLD and group 2 included 60 with COVID-19 free from CLD. All the included cases were reviewed to obtain data about general history, clinical examination laboratory investigations and mortality rate. Results: Compared to COVID-19 patients without chronic liver diseases, patients with COVID-19 and chronic liver diseases had a significant mortality rate (60% versus 20% respectively). Among patients with chronic liver diseases, the mortality rate was statistically significantly higher in decompensated cirrhosis (100%) followed by patients with hepatocellular carcinoma (80%) and the lowest mortality rate was found in decompensated cirrhosis (46.7%). Multivariate regression analysis showed that increasing age, decreased albumin concentration, and increasing INR and PT were independent predictors for mortality in patients with chronic liver diseases. Conclusion: COVID-19 in patients with chronic liver diseases had worse outcomes compared to COVID -19 in patients without chronic liver diseases. Among the chronic liver diseases decompensated liver disease was linked to the worst outcome.